Evidence map›Paper›PMID 24391884›Full record

ArticlePloS one2013

Endothelial dysfunction exacerbates renal interstitial fibrosis through enhancing fibroblast Smad3 linker phosphorylation in the mouse obstructed kidney.

Yu Bo Yang Sun, Xinli Qu, Xueling Li, David J Nikolic-Paterson, Jinhua Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. ResolvinDLaboratory investigation; a journal of technical methods and pathology · 2018
    Article
  12. Review
  13. Article
  14. Serum Endocan as a Predictive Marker for Decreased Urine Volume in Peritoneal Dialysis Patients.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  15. The JNK Signaling Pathway in Renal Fibrosis.Frontiers in physiology · 2017
    Review
  16. Article
  17. Article
  18. Inflammatory processes in renal fibrosis.Nature reviews. Nephrology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yu Bo Yang SunDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Xinli QuDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Xueling LiThe Key Laboratory of National Education Ministry for Mammalian Reproductive Biology and Biotechnology, Inner Mongolia University,Hohhot,Inner Mongolia, People's Republic of China.
David J Nikolic-PatersonDepartment of Nephrology, Monash Health and Monash University Department of Medicine, Clayton, Victoria, Australia.
Jinhua LiDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Monash University · AUInner Mongolia University · CNMonash Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial dysfunction and enhanced transforming growth factor-β (TGF-β)/Smad3 signalling are common features of progressive renal fibrosis. This study investigated a potential link between these mechanisms. In unilateral ureteric obstruction (UUO) we observed an acute (6 hr) down-regulation of nitric oxide synthase 3 (NOS3/eNOS) levels and increased phosphorylation of the linker region of Smad3 at T179 and S208 in Smad3/JNK complexes. These events preceded Smad3 C-terminal domain phosphorylation and the induction of myofibroblast proliferation at 48 hrs. Mice deficient in NOS3 showed enhanced myofibroblast proliferation and collagen accumulation compared to wild type mice in a 7 day UUO model. This was associated with enhanced phosphorylation of Smad3 T179 and S208 by 92% and 88%, respectively, whereas Smad3-C-terminal phosphorylation was not affected. Resolvin D1 (RvD1) can suppress renal fibrosis in the UUO model, and further analysis herein showed that RvD1 protected against endothelial dysfunction and suppressed Smad3/JNK complex formation with a consequent reduction in phosphorylation of Smad3 T179 and S208 by 78% and 65%, respectively, while Smad3 C-terminal phosphorylation was unaltered. In vitro, conditioned media from mouse microvascular endothelial cells (MMEC) treated with a general inhibitor of nitric oxide synthase (L-NAME) augmented the proliferation and collagen production of renal fibroblasts (NRK49F cells) compared to control MMEC media and this was associated with increased phosphorylation of JNK and Smad3 T179 and S208, whereas Smad3-C-terminal domain phosphorylation was unaffected. The addition of RvD1 to L-NAME treated MMEC abrogated these effects of the conditioned media on renal fibroblasts. Finally, Smad3 T179/V and S208/A mutations significantly inhibit TGF-β1 induced up-regulation collagen I promoter. In conclusion, these data suggest that endothelial dysfunction can exacerbate renal interstitial fibrosis through increased fibroblast proliferation and collagen production via enhanced Smad3 linker phosphorylation.

Indexed as

AnimalsBlotting, WesternCell ProliferationCells, CulturedCollagenCulture Media, ConditionedDocosahexaenoic AcidsEndothelium, VascularFibroblastsFibrosisImmunoprecipitationKidney DiseasesLuciferasesMaleMiceMice, Inbred C57BLCollagenCulture Media, ConditionedDocosahexaenoic AcidsLuciferasesNitric Oxide Synthase Type IIINos3 protein, mouseresolvin D1Smad3 ProteinSmad3 protein, mouseTransforming Growth Factor beta1

Identifiers

PMID24391884
PMCPMC3877161
OpenAlexW2011215643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.